Stockreport

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

IceCure Medical Ltd. - Ordinary Shares  (ICCM) 
PDF Interim Data confirm ProSense® cryoablation is highly effective for kidney tumors =3 cm and a safe procedure for kidney tumors =5 cm in people ineligible for surgery CAE [Read more]